Moffitt Cancer Center and Fulgent Pharma have formed a partnership to accelerate the development of personalized cancer therapies.

• Moffitt provides Fulgent access to clinical expertise and resources, prioritizing Fulgent’s clinical pipeline.
• Fulgent contributes its nanotherapeutics and genomics platforms.
• Co-development of personalized treatment options based on Moffitt’s scientific and immunology expertise, as well as Fulgent’s nano-particle platform and genetic testing capabilities.

The collaboration aims to transform patient care by unlocking precision medicine advancements. By tailoring therapies to individual patient needs, the partnership seeks to improve treatment outcomes and enhance the quality of life for cancer patients.

Fulgent has transformed paclitaxel, a chemotherapy drug with poor solubility, into a soluble form (FID-007) suitable for intravenous injection. FID-007 has shown promising results in Phase 1 clinical trials, with significant tumor reduction observed in various cancer types.

Moffitt’s strengths in clinical trials, patient screening, and data sharing support the rapid advancement of Fulgent’s clinical pipeline. The institution’s broad scientific knowledge and access to tissue samples enhance the co-development of personalized treatments.

The Moffitt-Fulgent partnership combines cutting-edge clinical capabilities with innovative nanotechnology and genomics to accelerate the development of precision oncology therapies. By leveraging their complementary strengths, the organizations aim to improve patient outcomes and bring lifesaving treatments closer to patients in need.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.